Pasithea Therapeutics (KTTA) Non Operating Income (2021 - 2026)

Pasithea Therapeutics has reported Non Operating Income for 6 years, with the latest figure at $2.0 million in Q1 2026.

• Quarterly Non Operating Income rose 1616.39% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (up 721.51% YoY) and the FY2025 annual result came in at $429612.0, up 24.39% from the prior year.
• Non Operating Income climbed to $2.0 million in Q1 2026 per KTTA's latest filing, from $145294.0 in the prior quarter.
• Over five years, Non Operating Income peaked at $2.0 million in Q1 2026 and troughed at -$335317.0 in Q3 2022.
• A 5-year average of $260652.8 and a median of $117229.5 in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2023 and 2026: Non Operating Income plunged 106.41% in 2023, then surged 1616.39% in 2026.
• Over 5 years, Non Operating Income stood at -$335317.0 in 2022, then jumped by 135.05% to $117518.0 in 2023, then tumbled by 30.32% to $81889.0 in 2024, then surged by 77.43% to $145294.0 in 2025, then surged by 1281.45% to $2.0 million in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $2.0 million, $145294.0, and $72635.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.